Abiomed, a subsidiary of J&J MedTech, announced positive results for the regular use of its Impella CP heart pump system.
Recent data from the DanGer Shock randomised controlled trial reveals significant long-term benefits of using Impella CP in patients suffering from heart attacks with cardiogenic shock.
The findings, presented at the European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine, indicate a 16.3% absolute reduction in mortality over a 10-year period when compared to standard care.
Additionally, patients treated with Impella CP experienced an average of 600 more days alive compared to the control group.
The data was shared by the trial’s principal investigator, Jacob Møller, highlighting an increase from the initial six-month data, which showed a 12.7% reduction in mortality risk.
J&J MedTech chief medical and scientific officer for heart recovery Navin Kapur said: “The long-term data from the DanGer Shock RCT released today validates the original findings and confirms that the survival benefit of Impella CP is durable and increases year-over-year.”
The Impella CP device is the first mechanical circulatory support system proven to provide both short-term and long-term survival benefits for patients with cardiogenic shock due to ST-elevation myocardial infarction (STEMI).
Following these findings, the American College of Cardiology and the American Heart Association upgraded Impella to a class 2a guideline in May 2024.
The trial, conducted at 14 sites across Denmark, Germany, and the UK, enrolled 360 participants between 2013 and 2023.
Cardiogenic shock remains a leading cause of in-hospital mortality for patients with STEMI, affecting up to 10% of the approximately 750,000 individuals who experience this type of heart attack annually in the US.
Impella, known as the smallest heart pump globally, temporarily assumes the heart’s pumping function, enabling the heart to rest and recover while ensuring the continuous flow of oxygenated blood. The treatment allows patients to return to their daily lives with their native heart and maintain or improve their quality of life.
